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Background: Clinical trials of carotid artery stenting (CAS) have often enrolled highly selected patients at a limited number of centers. Whether 
results from these studies are generalizable to those undergoing CAS in non-clinical trial settings is not clear. We compared patient characteristics 
and in-hospital outcomes in patients undergoing CAS within and not within clinical trials as part of the Carotid Artery Revascularization and 
Endarterectomy (CARE) Registry.
Methods: Patients age >= 18 enrolled in the CARE Registry who underwent CAS between April, 2005 and June, 2009 were identified. Clinical trial 
and non-clinical trial patients were compared, and then matched in a 1:1 fashion based on propensity score incorporating > 70 clinically relevant 
variables. Combined in-hospital death, MI or stroke was compared by group.
Results: A total of 6004 patients undergoing CAS were included in the analysis; of these, 3628 (60.4%) had been part of a clinical trial. Compared 
to non-clinical trial patients, clinical trial patients were older, had a higher prevalence of hypertension, dyslipidemia and ischemic heart disease, 
but a lower prevalence of symptomatic carotid disease. Combined death, MI or stroke was higher in non-clinical trial patients compared to clinical 
trial patients (5.4% vs. 3.9%, p = 0.005). After propensity score matching (n = 1452 per group), no significant difference in the primary outcome was 
observed between groups (5.4% for non-clinical trial vs. 4.3% for clinical trial, p = 0.17). However, in-hospital death (1.3% vs. 0.6%, p = 0.03) and 
combined death or MI (1.9% vs. 0.8%, p = 0.02) remained significantly higher in non-clinical trial patients after propensity-score matching.
Conclusions: Patients undergoing CAS within clinical trials have lower unadjusted rates of combined in-hospital death, MI or stroke compared to 
those not in clinical trials. Although differences in the primary outcome were no longer significant after propensity matching, in-hospital death and 
combined death or MI remained higher in the non-clinical trial population. Patients undergoing CAS outside of clinical trials may be at higher risk for 
adverse outcomes compared to matched patients from clinical trials.
